The potential for repositioning antithyroid agents as antiasthma drugs - 09/11/16
Doi : 10.1016/j.jaci.2016.04.047
Shoichi Suzuki, PhD a, Masahiro Ogawa, PhD a, Shoichiro Ohta, MD, PhD b, Kazuhiko Arima, MD, PhD a, Satoshi Nunomura, PhD a, Yasuhiro Nanri, PhD a, Yasutaka Mitamura, MD a, Tomohito Yoshihara, MD a, Yutaka Nakamura, MD, PhD c, Kohei Yamauchi, MD, PhD c, Kazuyuki Chibana, MD, PhD d, Yoshiki Ishii, MD, PhD d, James J. Lee, PhD e, Yasuaki Aratani, PhD f, Shigeru Kakuta, PhD g, h, Sachiko Kubo, PhD h, i, Yoichiro Iwakura, PhD h, i, Hiroki Yoshida, MD, PhD j, Kenji Izuhara, MD, PhD a 
a Division of Medical Biochemistry, Saga Medical School, Saga, Japan
b Department of Laboratory Medicine, Saga Medical School, Saga, Japan
c Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
d Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan
e Division of Pulmonary Medicine, Mayo Clinic Arizona, Scottsdale, Ariz
f Graduate School of Nanobioscience, Yokohama City University, Yokohama, Japan
g Department of Biomedical Science, Graduate School of Agricultural and Life Sciences, the University of Tokyo, Tokyo, Japan
h Center for Experimental Medicine and Systems Biology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
i Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan
j Division of Immunology, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
| This work was funded in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (S.S., grant no. 24591467; K.I., grant no. 25293224) and by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo (S. Kakuta, S. Kubo, Y.I., and H.Y., grant no. 201). |
|
| Disclosure of potential conflict of interest: S. Suzuki receives research support from the Japan Society for the Promotion of Science and holds a patent prophylactic or therapeutic agent for bronchial asthma and method for screening the same. S. Ohta holds a patent prophylactic or therapeutic agent for bronchial asthma and method for screening the same. K. Arima receives payment for lectures from Chugai Pharmaceuticals and Astellas Pharmaceuticals and holds a patent prophylactic or therapeutic agent for bronchial asthma and method for screening the same. J. J. Lee receives research support from the National Institute of Health. S. Kakuta receives research support from the joint Project of the Institute of Medical Science, the University of Tokyo. S. Kubo receives research support from the joint Project of the Institute of Medical Science, the University of Tokyo. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 138 - N° 5
P. 1458 - novembre 2016 Retour au numéro
Article précédent
- B-cell–specific STAT3 deficiency: Insight into the molecular basis of autosomal-dominant hyper-IgE syndrome
- Alisa Kane, Anthony Lau, Robert Brink, Stuart G. Tangye, Elissa K. Deenick
- Keratin-dependent thymic stromal lymphopoietin expression suggests a link between skin blistering and atopic disease
- Vinod Kumar, Matthias Behr, Dimitra Kiritsi, Andrea Scheffschick, Anja Grahnert, Melanie Homberg, Agnes Schwieger-Briel, Thilo Jakob, Leena Bruckner-Tuderman, Thomas M. Magin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?